jakafi guidanc pivot vitiligo studi design
confirm pt
messag report earn see preview includ
top bottom line estim beat well rais lower end
jakafi guidanc previous pipelin
catalyst remain track includ initi pivot topic ruxolitinib program
vitiligo final trial design confirm today call rais pt
reiter buy rate given convict sustain jakafi
growth approv indic addit upsid potenti topic ruxolitinib derm
opportun frontlin gvhd opportun itacitinib
top bottom line beat jakafi guidanc narrow report
revenu includ mileston revenu came higher
consensu includ jakafi sale
estim consensu respect result
manag rais lower end jakafi guidanc previous
today call oper expens estim
result report bottom line beat ep vs guggenheim
estim consensu estim reiter guidanc
jakafi growth continu driven demand jakafi beat driven
growth net sale manag state growth patient demand
confirm number new patient total patient across myelofibrosi
mf polycythemia vera pv indic grew qoq addit team report
encourag earli feedback recent jakafi snda approv treatment acut
graft-versus-host diseas agvhd earli quantifi impact
indic manag confirm inform indic metric volum
specialti distributor channel suggest uptak par expect
posit trend led manag increas lower end jakafi guidanc
well reiter long-term jakafi guidanc
pivot trial plan topic ruxolitinib vitiligo confirm track initi
year end follow discuss regul posit ph ii vitiligo dataset
confirm pivot program topic ruxolitinib vitiligo includ trial
patient random either ruxolitinib twice-a-day
bid vehicl primari endpoint percentag treat patient achiev
improv facial assess vitiligo area sever week
recal ph ii studi recent present world congress dermatolog
link patient treat topic ruxolitinib bid vs
patient treat vehicl importantli patient treat vehicl achiev f-
timepoint assess ph ii studi confirm plan initi
trial year end
three ph graft-versus-host diseas gvhd dataset read recal
jakafi grant fda approv treatment steroid-refractori agvhd may
link gain first approv gvhd market ph trial jakafi
gvhd track read year end per manag
guidanc recal random confirmatori trial evalu jakafi steroid-
refractori agvhd random trial evalu jakafi steroid-refractori
chronic gvhd addit on-going ph trial evalu itacitanib
treatment-nav agvhd expect read year end per manag guidanc
meanwhil ph studi evalu itacitanib treatment-nav cgvhd
on-going
page analyst certif import disclosur
pemigatinib program track manag confirm plan updat ph ii
data evalu pemigatinib cholangiocarcinoma
submit new drug applic nda file base studi year end recal
ph trial evalu pemigatinib cholangiocarcinoma initi
june addit studi evalu pemigatinib bladder cancer
continu dose cohort continu enrol enrol complet expect year
end potenti snda file next year per manag guidanc furthermor
plan ph ii tumor-agnost studi evalu pemigatinib patient
driver-activ fgfr across variou tumor type track open come
partner program capmatinib novn track nda file recal posit
data ph ii geometri trial evalu capmatinib patient local
advanced/metastat nsclc harbor skip mutat present
year meet novn confirm remain track submit nda
capmatinib
rais pt base revenu beat across portfolio slightli lower opex
previous model rais pt believ
still upsid potenti current valuat base convict sustain
jakafi growth approv indic topic ruxolitinib dermatolog opportun
atop derm read vitligo initi later year frontlin
gvhd opportun itacitinib top-line data read later year
model updat reflect earn updat adjust market model opex
figur reflect trend
page analyst certif import disclosur
valu per share previous use probabl adjust free cash flow
project jakafi iclusig olumi itacitinib topic ruxolitinib use discount
rate consist commerci stage biotech compani coverag
termin growth rate
 regulatori commerci setback
potenti emerg new competitor
lower product sale expect
risk intellectu properti risk manag execut
page analyst certif import disclosur
chang fair valu acquisition-rel conting
interest incom net
unreal gains-to-loss long-term invest
incom tax
balanc sheet statement flow
compani report guggenheim secur llc estim
page analyst certif import disclosur
